Nationwide Fund Advisors’s Lifecore Biomedical LFCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-19,025
Closed -$246K 1144
2017
Q3
$246K Hold
19,025
﹤0.01% 2540
2017
Q2
$283K Hold
19,025
﹤0.01% 2475
2017
Q1
$228K Sell
19,025
-3,121
-14% -$39.5K ﹤0.01% 2529
2016
Q4
$306K Sell
22,146
-2,234
-9% -$31K ﹤0.01% 2422
2016
Q3
$327K Sell
24,380
-1,985
-8% -$24K ﹤0.01% 2385
2016
Q2
$284K Hold
26,365
﹤0.01% 2439
2016
Q1
$277K Sell
26,365
-877
-3% -$9.63K ﹤0.01% 2382
2015
Q4
$322K Hold
27,242
﹤0.01% 2319
2015
Q3
$318K Hold
27,242
﹤0.01% 2349
2015
Q2
$393K Sell
27,242
-2,350
-8% -$33.9K ﹤0.01% 2376
2015
Q1
$413K Sell
29,592
-1,004
-3% -$13.9K ﹤0.01% 2333
2014
Q4
$423K Sell
30,596
-203
-0.7% -$2.62K ﹤0.01% 2281
2014
Q3
$377K Sell
30,799
-1,571
-5% -$19.6K ﹤0.01% 2366
2014
Q2
$404K Buy
32,370
+6,408
+25% +$75.4K ﹤0.01% 2374
2014
Q1
$290K Hold
25,962
﹤0.01% 2326
2013
Q4
$315K Sell
25,962
-476
-2% -$5.68K ﹤0.01% 2461
2013
Q3
$323K Buy
26,438
+1,168
+5% +$16.3K ﹤0.01% 2437
2013
Q2
$334K Buy
+25,270
New +$349K ﹤0.01% 2240

Other funds holding LFCR

Nationwide Fund Advisors's LFCR Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Lifecore Biomedical (LFCR) in Q4 2017, closing a stake of 19,025 shares — an estimated $246K sold.

Nationwide Fund Advisors first reported a position in LFCR in Q2 2013 and held it in 18 quarters. The position peaked at $423K in Q4 2014. 91 funds tracked by Wall St. Rank hold LFCR as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Lifecore Biomedical position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 19,025 Lifecore Biomedical shares in Q4 2017, an estimated $246K.
  • Nationwide Fund Advisors first reported a position in Lifecore Biomedical in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Lifecore Biomedical position peaked at $423K in Q4 2014.
  • 91 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.